睿知中国医院研究地图
候选清单

北京首都医科大学

首都医科大学附属北京友谊医院

Beijing Friendship Hospital

在本站收录的 53 种疾病中,这家医院列在其中 26 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

官方链接已于 2026-11-08 打开核对。

联系这家医院

首都医科大学附属北京友谊医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 食管鳞状细胞癌Oesophageal squamous cell carcinoma12 篇牵头论文
  2. 肝细胞癌Hepatocellular carcinoma51 篇牵头论文牵头 1 项开放试验
  3. 胃癌Stomach cancer45 篇牵头论文牵头 7 项开放试验
  4. 肝母细胞瘤Hepatoblastoma1 篇牵头论文
  5. 视网膜母细胞瘤Retinoblastoma1 篇牵头论文
  6. 骨肉瘤Osteosarcoma2 篇牵头论文
  7. 胃肠道间质瘤Gastrointestinal stromal tumour2 篇牵头论文
  8. 神经母细胞瘤Neuroblastoma47 篇牵头论文
  9. 尤文肉瘤Ewing sarcoma1 篇牵头论文
  10. 多发性骨髓瘤Multiple myeloma1 篇牵头论文
  11. 噬血细胞性淋巴组织细胞增生症Haemophagocytic lymphohistiocytosis52 篇牵头论文牵头 3 项开放试验
  12. 血友病 AHaemophilia A0 篇牵头论文
  13. 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura0 篇牵头论文
  14. IgG4相关性疾病IgG4-related disease12 篇牵头论文
  15. 重症肌无力Myasthenia gravis1 篇牵头论文
  16. 肝豆状核变性Wilson disease4 篇牵头论文牵头 1 项开放试验
  17. 胆道闭锁Biliary atresia4 篇牵头论文
  18. 大动脉炎Takayasu arteritis2 篇牵头论文
  19. 特发性肺纤维化Idiopathic pulmonary fibrosis1 篇牵头论文
  20. 庞贝病Pompe disease1 篇牵头论文
  21. 白塞病Behçet disease1 篇牵头论文
  22. IgA 肾病IgA nephropathy0 篇牵头论文
  23. 戈谢病Gaucher disease2 篇牵头论文
  24. 原发性胆汁性胆管炎Primary biliary cholangitis12 篇牵头论文牵头 1 项开放试验
  25. 原发性硬化性胆管炎Primary sclerosing cholangitis4 篇牵头论文
  26. 先天性巨结肠Hirschsprung disease0 篇牵头论文

未列出的收录疾病:鼻咽癌、脊索瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、β 地中海贫血、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、烟雾病、抗 NMDA 受体脑炎、肝包虫病、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、杜氏肌营养不良、Alport 综合征、尼曼-匹克病 C 型、成骨不全症、先天性膈疝、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

食管鳞状细胞癌

Oesophageal squamous cell carcinoma

2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 12 篇,占 0.4%。

牵头论文
12
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 3320212022: 4420222023: 2220232024: 1120242025: 222025

北京有 13 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    分期
    I期
    开始
    2022-10
    登记号
    NCT05208762

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题免疫治疗影像与人工智能分子标志物与基因
论文中的科室消化/肝病科肿瘤内科

这些论文过半是实验室或动物研究。

牵头的论文12
  1. Unraveling the tumor microenvironment of esophageal squamous cell carcinoma through single-cell sequencing: A comprehensive review.2025Biochimica et biophysica acta. Reviews on cancer
  2. Predicting pathological response of resectable esophageal squamous cell carcinoma to neoadjuvant anti-PD-1 with chemotherapy using serum inflammation indexes.2025Scientific reports免费全文
  3. Lysophosphatidic acid promotes ESCC progression by increasing the level of CCL2 secreted by esophageal epithelial cells.2024The journal of gene medicine
  4. Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis.2023BMC cancer免费全文
  5. Endoscopic Submucosal Dissection for Hypervascularized Esophageal Squamous Cell Carcinoma in Decompensated Cirrhosis With Esophageal Varices and Scars.2023The American journal of gastroenterology免费全文
  6. Expression and Significance of N-myc downstream regulated gene 2 in the process of Esophageal Squamous Cell Carcinogenesis.2022Bioengineered免费全文
  7. Clinical characteristics, prognostic factors, and survival trends in esophageal neuroendocrine carcinomas: A population-based study.2022Cancer medicine免费全文
  8. Porphyromonas gingivalis secretion leads to dysplasia of normal esophageal epithelial cells via the Sonic hedgehog pathway.2022Frontiers in cellular and infection microbiology免费全文
  9. Circ_0001821 Affects Proliferation and the Cell Cycle in Esophageal Squamous Cell Carcinoma by Elevating BTRC-Mediated IKBA Ubiquitination.2022Molecular cancer research : MCR
  10. Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.2021Annals of palliative medicine
  11. Comorbid early esophageal cancer and Gongylonema pulchrum infection: a case report.2021BMC gastroenterology免费全文
  12. Lysophosphatidic acid mediated PI3K/Akt activation contributed to esophageal squamous cell cancer progression.2021Carcinogenesis
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. Chemoprevention of Esophageal Squamous Cell Carcinoma (ESCC) With Aspirin and Tea Polyphenols状态不明NCT01496521牵头方III期2012-01 启动
  2. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors正在招募NCT05208762研究中心I期2022-10 启动
  3. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma已终止NCT05461794研究中心II期2022-10 启动
  4. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma已完成NCT04732494研究中心II期2021-03 启动
  5. Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions状态不明NCT04170257研究中心不分期2019-10 启动
  6. A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma已完成NCT04187352研究中心III期2019-12 启动
  7. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03430843研究中心III期2018-01 启动
  8. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma已完成NCT03783442研究中心III期2018-12 启动
PubMed 以外找到的论文(未计入)2
  1. Data from Circ_0001821 Affects Proliferation and the Cell Cycle in Esophageal Squamous Cell Carcinoma by Elevating BTRC-Mediated IKBA Ubiquitination2023未列出期刊其他
  2. Data from Circ_0001821 Affects Proliferation and the Cell Cycle in Esophageal Squamous Cell Carcinoma by Elevating BTRC-Mediated IKBA Ubiquitination2023未列出期刊其他

打开 PubMed 检索ClinicalTrials.gov

癌症

肝细胞癌

Hepatocellular carcinoma

2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 51 篇,占 0.4%。

牵头论文
51
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 7720212022: 151520222023: 9920232024: 111120242025: 882025

北京有 17 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 即将招募
    HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B
    分期
    未注明
    开始
    2026-08
    登记号
    NCT07780357

    年龄 18 岁 至 未注明(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  2. 正在招募
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    分期
    III期
    开始
    2023-05
    登记号
    NCT05862337

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 43 家列出的医院为研究中心上海、乌鲁木齐、兰州、北京、南充、南宁、南昌、南通、台州、合肥、天津、宁波、常州、广州、成都、杭州、沈阳、泸州、济南、海口、温州、福州、蚌埠、西安、郑州、重庆、长春、长沙

  3. 正在招募
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    分期
    I期
    开始
    2022-10
    登记号
    NCT05208762

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题影像、人工智能与早期发现乙肝与肝硬化复发与预后
论文中的科室影像/核医学科消化/肝病科普外/肝胆胰外科临床试验/研究机构
牵头的论文51
  1. Unstable Recompensation: An Intermediate Subtype in Patients With HBV-Related Decompensated Cirrhosis.2026Alimentary pharmacology & therapeutics免费全文
  2. Role of the nucleotide excision repair function of CETN2 in the inhibition of the sensitivity of hepatocellular carcinoma cells to oxaliplatin.2025Carcinogenesis
  3. Predicting Treatment Response to Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients using a Deep Learning-based Approach.2025Current medical imaging免费全文
  4. Novel immune-related prognostic models for patients with hepatocellular carcinoma after curative resection.2025Hepatology international
  5. Stage-Specific Transcriptome Landscape of Hepatocellular Carcinoma: Insights From Super and Poor Survivors With Prognostic Signature Identification.2025Journal of digestive diseases
  6. Monitoring Sorafenib Resistance and Efficacy in Hepatocellular Carcinoma Using [18F]Alfatide II and [18F]Fluorodeoxyglucose Positron Emission Tomography.2025Molecular pharmaceutics
  7. Novel role of general transcript factor IIH subunit 2 (GTF2H2) in the development and sex disparity of hepatocellular carcinoma.2025Oncogene
  8. Deep learning for hepatocellular carcinoma recurrence before and after liver transplantation: a multicenter cohort study.2025Scientific reports免费全文
  9. Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis.2025The oncologistRCT免费全文
  10. Preoperative prediction power of radiomics and non-radiomics methods based on MRI for early recurrence in hepatocellular carcinoma: a systemic review and meta-analysis.2024Abdominal radiology (New York)
  11. Deep learning-based arterial subtraction images improve the detection of LR-TR algorithm for viable HCC on extracellular agents-enhanced MRI.2024Abdominal radiology (New York)
  12. The timing phase affected the inconsistency of APHE subtypes of liver observations in patients at risk for HCC on the multi-hepatic arterial phase imaging.2024Abdominal radiology (New York)
  13. The Diagnostic Accuracy Between Radiomics Model and Non-radiomics Model for Preoperative of Microvascular Invasion of Solitary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.2024Academic radiology
  14. Inter-reader agreement of LI-RADS treatment response algorithm among three readers with different seniorities for hepatocellular carcinoma after locoregional therapy.2024Acta radiologica (Stockholm, Sweden : 1987)
  15. Optimizing LI-RADS: ancillary features screened from LR-3/4 categories can improve the diagnosis of HCC on MRI.2024BMC gastroenterology免费全文
  16. Preoperative evaluation of microvascular invasion in hepatocellular carcinoma with a radiological feature-based nomogram: a bi-centre study.2024BMC medical imaging免费全文
  17. Sequencing of systemic therapy in unresectable hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis of randomized clinical trials.2024Critical reviews in oncology/hematology
  18. Risk of transplant rejection associated with ICIs prior to liver transplantation in HCC: A multicenter retrospective study.2024International immunopharmacology
  19. Changing spectrum and mortality disparities of etiology of liver cirrhosis in Beijing, China.2024Journal of medical virology
  20. Ablative Treatments and Surgery for Early-Stage Hepatocellular Carcinoma: A Network Meta-Analysis.2024The Journal of surgical research
  21. MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma.2023BMC medical imaging免费全文
  22. Hepatocellular carcinoma prediction model performance decreases with long-term antiviral therapy in chronic hepatitis B patients.2023Clinical and molecular hepatology免费全文
  23. The clinical management of hepatocellular carcinoma in China: Progress and challenges.2023Clinical and molecular hepatology免费全文
  24. Comparison of quantitative volumetric analysis and linear measurement for predicting the survival of Barcelona Clinic Liver Cancer 0- and A stage hepatocellular carcinoma after radiofrequency ablation.2023Diagnostic and interventional radiology (Ankara, Turkey)免费全文
  25. The role of 18F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy.2023Frontiers in immunology免费全文
  26. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding.2023Hepatology international
  27. Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis.2023Hepatology international
  28. Two-year free of complications during antiviral therapy predicts stable re-compensation in immediate-treatment HBV-related decompensated cirrhosis.2023Scandinavian journal of gastroenterology
  29. Platelet membrane-derived microparticles may be biomarkers in patients with hepatocellular carcinoma and can promote the invasion and metastasis of hepatoma carcinoma cells.2023Transfusion
  30. Histological assessment based on liver biopsy: the value and challenges in NASH drug development.2022Acta pharmacologica Sinica免费全文
  31. Diagnostic performance of imaging features in the HBP of gadoxetate disodium-enhanced MRI for microvascular invasion in hepatocellular carcinoma: a meta-analysis.2022Acta radiologica (Stockholm, Sweden : 1987)
  32. High-throughput circular RNA sequencing reveals the profiles of circular RNA in non-cirrhotic hepatocellular carcinoma.2022BMC cancer免费全文
  33. Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features.2022BMC medical imaging免费全文
  34. CT-based skeletal muscle loss for predicting poor survival in patients with hepatocellular carcinoma experiencing curative hepatectomy plus adjuvant transarterial chemoembolization: a preliminary retrospective study.2022European journal of medical research免费全文
  35. Systematic review and meta-analysis: impact of anti-viral therapy on portal hypertensive complications in HBV patients with advanced chronic liver disease.2022Hepatology international
  36. Roles of small extracellular vesicles in the development, diagnosis and possible treatment strategies for hepatocellular carcinoma (Review).2022International journal of oncology免费全文
  37. Clinical evidence of outcomes following liver transplantation in patients with nonalcoholic steatohepatitis: An updated meta-analysis and systematic review.2022International journal of surgery (London, England)
  38. Predictive value of hepatic venous pressure gradient and efficacy and significance of early PTVE for gastrointestinal bleeding after TACE for liver cancer.2022Journal of cancer research and therapeuticsRCT
  39. Predictors of mid-term survival after liver transplantation in patients with NAFLD cirrhosis.2022Liver international : official journal of the International Association for the Study of the Liver
  40. Predicting hepatocellular carcinoma early recurrence after ablation based on magnetic resonance imaging radiomics nomogram.2022Medicine免费全文
  41. Downregulation of HULC Induces Ferroptosis in Hepatocellular Carcinoma via Targeting of the miR-3200-5p/ATF4 Axis.2022Oxidative medicine and cellular longevity免费全文
  42. Baicalin suppresses the progression of Type 2 diabetes-induced liver tumor through regulating METTL3/m6A/HKDC1 axis and downstream p-JAK2/STAT1/clevaged Capase3 pathway.2022Phytomedicine : international journal of phytotherapy and phytopharmacology
  43. Comparative Performance of 14 HCC Prediction Models in CHB: A Dynamic Validation at Serial On-Treatment Timepoints.2022The American journal of gastroenterology
  44. Exosome-derived GTF2H2 from Huh7 cells can inhibit endothelial cell viability, migration, tube formation, and permeability.2022Tissue & cell
  45. Role of tight junction-associated MARVEL protein marvelD3 in migration and epithelial-mesenchymal transition of hepatocellular carcinoma.2021Cell adhesion & migration免费全文
  46. Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation.2021Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  47. Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis.2021Hepatology internationalRCT
  48. Prediction of liver-related events in patients with compensated HBV-induced cirrhosis receiving antiviral therapy.2021Hepatology international
  49. Does Training in LI-RADS Version 2018 Improve Readers' Agreement with the Expert Consensus and Inter-reader Agreement in MRI Interpretation?2021Journal of magnetic resonance imaging : JMRI
  50. Magnetic resonance radiomics signatures for predicting poorly differentiated hepatocellular carcinoma: A SQUIRE-compliant study.2021Medicine免费全文
  51. Apoptosis-induced translocation of centromere protein F in its corresponding autoantibody production in hepatocellular carcinoma.2021Oncoimmunology免费全文
中文论文(未计入)5
  1. [Application and prospects of magnetic resonance imaging techniques in the diagnosis and evaluation of hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Construction of a stable centromere protein F overexpression cell model of hepatocellular carcinoma using CRISPR activation system].2023Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  3. [Expression and Clinical Significance of ATP Citrate Lyase in Hepatocellular Carcinoma].2023Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  4. [Low-level viremia-induced liver fibrosis and hepatocellular carcinoma in chronic hepatitis B].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  5. [Correlation among age, sex, and liver diseases-related mortality risk in patients with hepatitis B virus-related liver cirrhosis].2021Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
它在 ClinicalTrials.gov 上的全部试验(任何状态)5
  1. HCC Risk Prediction Model Based on Multimodal Data in Chronic Hepatitis B即将招募NCT07780357牵头方2026-08 启动
  2. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.正在招募NCT05862337研究中心III期2023-05 启动
  3. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors正在招募NCT05208762研究中心I期2022-10 启动
  4. A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma已完成NCT03434379研究中心III期2018-03 启动
  5. Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma已完成NCT01988493研究中心I/II期2014-01 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

胃癌

Stomach cancer

2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 45 篇,占 0.5%。

牵头论文
45
2021–2025 年
牵头试验
16
任何状态,ClinicalTrials.gov
牵头的开放试验
7
正在或即将招募
作为研究中心的开放试验
4
由其他机构牵头
每年牵头的论文数
2021: 5520212022: 6620222023: 141420232024: 9920242025: 10102025

北京有 15 家医院列在胃癌下全国有 218 家医院列在胃癌下

这家医院参与的开放试验 11

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy
    分期
    不分期
    开始
    2026-03
    登记号
    NCT07441850

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  2. 正在招募
    Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset
    分期
    未注明
    开始
    2026-05
    登记号
    NCT07747688

    年龄 18 岁 至 90 岁(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  3. 正在招募
    Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer
    分期
    不分期
    开始
    2026-08
    登记号
    NCT07835087

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  4. 正在招募
    Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
    分期
    II期
    开始
    2025-11
    登记号
    NCT07315854

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  5. 正在招募
    Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
    分期
    II期
    开始
    2025-05
    登记号
    NCT07353684

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  6. 正在招募
    Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)
    分期
    不分期
    开始
    2024-02
    登记号
    NCT06788548

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  7. 正在招募
    Validating a Medical AI Fine-Tuning Platform for Major Diseases
    分期
    未注明
    开始
    2024-11
    登记号
    NCT07795645

    年龄 18 岁 至 未注明(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  8. 正在招募
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    分期
    III期
    开始
    2026-04
    登记号
    NCT07385703

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 62 家列出的医院为研究中心上海、临沂、乌鲁木齐、兰州、北京、南京、南充、南昌、厦门、合肥、天津、太原、安阳、常州、广州、徐州、成都、扬州、承德、昆明、杭州、武汉、汕头、沈阳、洛阳、济南、海口、石家庄、福州、苏州、西安、郑州、重庆、长春、长沙、青岛

  9. 正在招募
    Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
    分期
    III期
    开始
    2026-09
    登记号
    NCT07700979

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 4 家列出的医院为研究中心上海、北京、广州

  10. 正在招募
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    分期
    未注明
    开始
    2025-02
    登记号
    NCT06846996

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 31 家列出的医院为研究中心上海、北京、南京、台州、天津、太原、广州、徐州、杭州、汕头、沈阳、海口、福州、郑州、长春

  11. 正在招募
    A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
    分期
    I期
    开始
    2022-10
    登记号
    NCT05208762

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心上海、北京

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题早期发现与内镜影像与人工智能腹膜转移与晚期
论文中的科室消化/肝病科普外/肝胆胰外科肿瘤内科病理/检验科
牵头的论文45
  1. Comparison on the reflux and nutritional status of different reconstruction methods after laparoscopic proximal gastrectomy: a systematic review and network meta-analysis.2026Updates in surgery免费全文
  2. Clinicopathological characteristics of 30 cases of pyloric gland adenoma: a single center case series.2025BMC gastroenterology免费全文
  3. Lectin-affinity glycosylation pattern analysis of plasma extracellular vesicles: An all-in-one clinical assessment for gastric cancer diagnosis and treatment.2025Cancer letters
  4. Fusobacterium nucleatum drives gastric cancer metastasis via Gbp-CypA-NF-κB-mediated CXCL8 crosstalk between tumor cells and mast cells.2025Cell communication and signaling : CCS免费全文
  5. Helicobacter pylori CagA promotes gastric cancer immune escape by upregulating SQLE.2025Cell death & disease免费全文
  6. Functions and Clinical Applications of Exosomes in Gastric Cancer.2025International journal of biological sciences免费全文
  7. Generation of surgical reports for lymph node dissection during laparoscopic gastric cancer surgery based on artificial intelligence.2025International journal of computer assisted radiology and surgery
  8. Efficient Metabolomics Profiling from Plasma Extracellular Vesicles Enables Accurate Diagnosis of Early Gastric Cancer.2025Journal of the American Chemical Society
  9. Prognostic implications of the interaction between intratumoral microbiome and immune response in gastric cancer.2025Microbiology spectrum免费全文
  10. Incidental Finding of a Primary Polypoid Low-Grade B-Cell Gastric Lymphoma Managed with Chemotherapy.2025The American journal of case reports免费全文
  11. Development and validation of a nomogram incorporating dietary factors for predicting Helicobacter pylori-negative early gastric cancer risk.2025World journal of gastroenterology免费全文
  12. Clinicopathologic and endoscopic characteristics of ten patients with gastric hamartomatous inverted polyp: a single center case series.2024BMC gastroenterology免费全文
  13. Chinese national clinical practice guidelines on the prevention, diagnosis, and treatment of early gastric cancer.2024Chinese medical journal免费全文
  14. Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: A systematic review with meta-analysis.2024Critical reviews in oncology/hematology
  15. Risk factors and a nomogram for predicting local recurrence in adult patients with early gastric cancer after endoscopic submucosal dissection.2024Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  16. Investigating biomechanical alterations and emptying patterns after various gastrojejunostomy strategy.2024Food research international (Ottawa, Ont.)
  17. A nomogram for predicting survival based on hemoglobin A1c and circulating tumor cells in advanced gastric cancer patients receiving immunotherapy.2024International immunopharmacology
  18. Artificial intelligence for automatic surgical phase recognition of laparoscopic gastrectomy in gastric cancer.2024International journal of computer assisted radiology and surgery
  19. Assessment of risk factors of lymph node metastasis and prognosis of Siewert II/III adenocarcinoma of esophagogastric junction: A retrospective study.2024Medicine免费全文
  20. Helicobacter pylori promotes gastric fibroblast proliferation and migration by expulsing exosomal miR-124-3p.2024Microbes and infection
  21. LncRNA CASC19 promotes gastric cancer progression through preventing CREB1 protein ubiquitin/proteasome-dependent degradation.2023Carcinogenesis
  22. LncRNA CASC19: a novel oncogene involved in human cancer.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  23. Efficacy and safety of combination chemotherapy regimens containing taxanes for first-line treatment in advanced gastric cancer.2023Clinical and experimental medicine
  24. Both extracellular vesicles from helicobacter pylori-infected cells and helicobacter pylori outer membrane vesicles are involved in gastric/extragastric diseases.2023European journal of medical research免费全文
  25. TRIM28 suppresses cancer stem-like characteristics in gastric cancer cells through Wnt/β-catenin signaling pathways.2023Experimental biology and medicine (Maywood, N.J.)免费全文
  26. Anthracycline chemicals with anthracyclinone structure exert antitumor effects by inhibiting angiogenesis and lymphangiogenesis in a xenografted gastric tumor model.2023Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  27. Predictive performance of radiomics for peritoneal metastasis in patients with gastric cancer: a meta-analysis and radiomics quality assessment.2023Journal of cancer research and clinical oncology免费全文
  28. Identification and evaluation of novel serum autoantibody biomarkers for early diagnosis of gastric cancer and precancerous lesion.2023Journal of cancer research and clinical oncology免费全文
  29. Safety and efficacy of augmented-rectangle technique versus delta-shaped anastomosis for treating gastric cancer in total laparoscopic distal gastrectomy.2023Langenbeck's archives of surgery
  30. Safety and efficacy of laparoscopic proximal gastrectomy with SOFY versus laparoscopic total gastrectomy with Roux-en-Y for treating cT1-2 Siewert II/III adenocarcinoma of the esophagogastric junction: a single-center prospective cohort stu2023Langenbeck's archives of surgery
  31. Circulating Tumor Cells as Diagnostic Markers of Early Gastric Cancer and Gastric Precancerous Lesions.2023Oncology
  32. Endoscopic and clinicopathologic features of early gastric signet ring cell carcinoma ≤20 mm: a retrospective observational study.2023Scandinavian journal of gastroenterology
  33. Comparison of endoscopic submucosal dissection outcomes between early gastric cardiac and non-cardiac cancers: a retrospective single-center study.2023Scandinavian journal of gastroenterology
  34. Autoimmune gastritis with a gastric hamartomatous inverted polyp and two hyperplastic polyps: a case report.2023The Journal of international medical research免费全文
  35. External validation of the BEST-J score and a new risk prediction model for ESD delayed bleeding in patients with early gastric cancer.2022BMC gastroenterology免费全文
  36. MiR-1298-5p level downregulation induced by Helicobacter pylori infection inhibits autophagy and promotes gastric cancer development by targeting MAP2K6.2022Cellular signalling
  37. Deep biopsy via endoscopic submucosal dissection for primary gastric amyloidosis.2022Endoscopy
  38. Immune Profiling in Gastric Cancer Reveals the Dynamic Landscape of Immune Signature Underlying Tumor Progression.2022Frontiers in immunology免费全文
  39. Gastric lesions in patients with autoimmune metaplastic atrophic gastritis: a retrospective study in a single center.2022Scandinavian journal of gastroenterology
  40. Short-term outcomes of three rare cases of intramucosal Epstein-Barr virus-associated gastric cancer treated with endoscopic submucosal dissection.2022The Journal of international medical research免费全文
  41. Leukemia inhibitory factor promotes gastric cancer cell proliferation, migration, and invasion via the LIFR-Hippo-YAP pathway.2021Annals of the New York Academy of Sciences
  42. The Significance of Exosomal RNAs in the Development, Diagnosis, and Treatment of Gastric Cancer.2021Genes免费全文
  43. IL-15-induced lymphocytes as adjuvant cellular immunotherapy for gastric cancer.2021Investigational new drugs
  44. Efficacy and safety of sintilimab-based regimens against advanced gastric and gastroesophageal junction adenocarcinoma.2021Journal of cancer research and therapeutics
  45. Asporin represses gastric cancer apoptosis via activating LEF1-mediated gene transcription independent of β-catenin.2021Oncogene
中文论文(未计入)3
  1. [Application research of endoscopic-laparoscopic regional gastric resection combined with sentinel lymph node basin dissection in patients with early gastric cancer].2025Zhonghua wai ke za zhi [Chinese journal of surgery]
  2. [Pathological features of early gastric cancer and its background mucosa after eradication of Helicobacter pylori and their implications for biopsy diagnosis].2023Zhonghua bing li xue za zhi = Chinese journal of pathology
  3. [Analysis of the clinical confusion and controversy of esophagogastric junction tumor from basic anatomy].2021Zhonghua wai ke za zhi [Chinese journal of surgery]
它在 ClinicalTrials.gov 上的全部试验(任何状态)25
  1. Retrospective Analysis of Early Gastric Cancer Patients Based on Prospective Clinical Dataset正在招募NCT07747688牵头方2026-05 启动
  2. Image-Guided Platform-Assisted Sentinel Lymph Node Retrieval in Early Gastric Cancer正在招募NCT07835087牵头方不分期2026-08 启动
  3. Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy正在招募NCT07441850牵头方不分期2026-03 启动
  4. Iparomlimab and Tuvonralimab (QL1706) Combined With Chemotherapy for Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer正在招募NCT07315854牵头方II期2025-11 启动
  5. Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer正在招募NCT07353684牵头方II期2025-05 启动
  6. Fluorescence Guided Laparoscopic-Endoscopic Cooperative Sentinel Lymph Node Navigation Surgery Strategy for Early Gastric Cancer(IDEAL Stage 2b)正在招募NCT06788548牵头方不分期2024-02 启动
  7. Validating a Medical AI Fine-Tuning Platform for Major Diseases正在招募NCT07795645牵头方2024-11 启动
  8. Exosome-based Liquid Biopsies for Upper Gastrointestinal Cancers Diagnosis状态不明NCT06278064牵头方2024-02 启动
  9. Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis状态不明NCT06363123牵头方2024-03 启动
  10. Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis已完成NCT06109805牵头方2023-10 启动
  11. Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer状态不明NCT04258644牵头方II期2020-03 启动
  12. Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer状态不明NCT04258657牵头方II期2020-03 启动
  13. Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer状态不明NCT04345783牵头方II期2018-01 启动
  14. Expanded Indications of Endoscopic Submucosal Dissection for Early Gastric Cancer in China已完成NCT06869356牵头方2018-05 启动
  15. A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer状态不明NCT03271073牵头方II期2016-02 启动
  16. Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric Cancer状态不明NCT02325999牵头方早期I期2013-12 启动
  17. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.正在招募NCT07385703研究中心III期2026-04 启动
  18. Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma正在招募NCT07700979研究中心III期2026-09 启动
  19. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China正在招募NCT06846996研究中心2025-02 启动
  20. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors正在招募NCT05208762研究中心I期2022-10 启动
  21. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer进行中,不再招募NCT05180734研究中心III期2022-02 启动
  22. Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension已完成NCT04882241研究中心III期2020-07 启动
  23. A Study to Confirm the Accuracy of Locally Advanced Gastric Cancer Diagnosis状态不明NCT04440605研究中心2020-07 启动
  24. HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer状态不明NCT04486651研究中心III期2020-09 启动
  25. Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer已终止NCT02867839研究中心III期2017-04 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

肝母细胞瘤

Hepatoblastoma

2021–2025 年中国大陆作者发表的 154 篇肝母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.7%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 9 家医院列在肝母细胞瘤下全国有 88 家医院列在肝母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肝母细胞瘤开放试验。

这些数字背后的记录
论文中的科室病理/检验科消化/肝病科

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

北京有 10 家医院列在视网膜母细胞瘤下全国有 196 家医院列在视网膜母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的视网膜母细胞瘤开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

癌症

骨肉瘤

Osteosarcoma

2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.09%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 1120232024: 0020242025: 002025

北京有 48 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

癌症

胃肠道间质瘤

Gastrointestinal stromal tumour

2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.4%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

北京有 23 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。

这些数字背后的记录
论文中的科室普外/肝胆胰外科影像/核医学科
牵头的论文2
  1. Survival outcomes in small intestine tumors: The role of duodenum, jejunum, and ileum.2025International journal of cancer
  2. The Value of Computed Tomography in Differentiating Heterotopic Pancreas from Small Gastrointestinal Stromal Tumor.2024Discovery medicine
早期论文(2016–2020 年)1
  1. Gastric sub-epithelial tumors: identification of gastrointestinal stromal tumors using CT with a practical scoring method.2019Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 47 篇,占 4.2%。

牵头论文
47
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 5520222023: 6620232024: 9920242025: 20202025

北京有 24 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科
牵头的论文47
  1. Solitary Humeral Metastasis in the Absence of Detectable Primary Neuroblastoma on Triple-tracer Imaging With 18F-FDG, 123I-MIBG, and 68Ga-DOTATATE.2026Clinical nuclear medicine
  2. False Positive of 123 I-MIBG Caused by Ectopic Thymic Rebound Hyperplasia in a Pediatric Neuroblastoma.2026Clinical nuclear medicine
  3. Unusual Initial Presentation of Epileptic Seizures in a Pediatric Patient With Neuroblastoma Detected by 18 F-FDG PET/CT Imaging.2026Clinical nuclear medicine
  4. 18 F-FDG PET/CT Demonstrates Left Adrenal Neuroblastoma in a Pediatric Patient With Beckwith-Wiedemann Syndrome.2026Clinical nuclear medicine
  5. 68 Ga-DOTATATE Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Pediatric Neuroblastoma.2026Clinical nuclear medicine
  6. Comparison of Iodine-123 Metaiodobenzylguanidine scintigraphy with SPECT/CT and Fluorine-18-aluminum fluoride-1,4,7-triazacyclononane-1,4,7-triacetic acid-octreotide PET/CT in recurrent High-risk neuroblastoma after complete remission.2026European journal of nuclear medicine and molecular imaging
  7. 18F-FDG PET/CT volumetric parameter predicts prognosis for neuroblastoma with MYCN gain.2025Abdominal radiology (New York)
  8. Application of modified Curie and SIOPEN skeleton scoring systems in 18F-AlF-NOTA-octreotide PET/CT for neuroblastoma.2025Annals of nuclear medicine
  9. The baseline 18F-FDG PET/CT imaging features in pediatric patients with congenital neuroblastoma.2025BMC medical imaging
  10. The prognostic significance of semi-quantitative metabolic parameters and tumoral metabolic activity based on 123I-MIBG SPECT/CT in pretreatment neuroblastoma patients.2025Cancer imaging : the official publication of the International Cancer Imaging Society
  11. The Role of 18 F-AlF-NOTA-Octreotide PET/CT in the Evaluation of Central Nervous System Metastases in Neuroblastoma : A Preliminary Study.2025Clinical nuclear medicine
  12. Completely Negative 123 I-MIBG SPECT/CT, but Strong Positive 68 Ga-DOTATATE PET/CT of Multiple Metastases in a Neuroblastoma Patient.2025Clinical nuclear medicine
  13. Recurrent Solitary Pleural Metastasis Originating From Neuroblastoma as Demonstrated by 123I-MIBG Scan.2025Clinical nuclear medicine
  14. Pseudoprogression on 68Ga-DOTATATE PET/CT in a Pediatric Patient With Neuroblastoma.2025Clinical nuclear medicine
  15. Positive 18 F-FDG PET/CT and Negative 123 I-MIBG SPECT/CT Imaging in an Unusual Diaphragmatic Metastasis From Ganglioneuroblastoma.2025Clinical nuclear medicine
  16. Incidental Detection of Choroid Plexus Metastasis From Neuroblastoma Demonstrated by 68 Ga-DOTATATE PET/CT.2025Clinical nuclear medicine
  17. False-Positive Uptake of 123 I-MIBG in the Basal Ganglion in a Pediatric Neuroblastoma Patient.2025Clinical nuclear medicine
  18. 68 Ga-DOTATATE PET/CT Demonstrated More Lesions of Leptomeningeal Metastases Compared With 123 I-MIBG SPECT/CT in a Pediatric Neuroblastoma Patient.2025Clinical nuclear medicine
  19. Concurrent Intracranial and Spinal Dural Metastases Demonstrated by 68 Ga-DOTATATE PET/CT With Negative 123 I-MIBG SPECT/CT in a Pediatric Neuroblastoma Patient.2025Clinical nuclear medicine
  20. A False-Negative 123 I-MIBG SPECT/CT With True-Positive 68 Ga-DOTATATE PET/CT in a Patient With Neuroblastoma Following 177 Lu-DOTATATE Therapy.2025Clinical nuclear medicine
  21. Predictive value of multiparametric diagnostic model based on 2-[18F]-fluoro-D-glucose (2-[18F]-FDG) positron emission tomography/computed tomography (PET/CT) metabolic parameters in differentiating between neuroblastoma and ganglioneurobla2025Clinical radiology
  22. Radiomics analysis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography for differentiating the histological classification of peripheral neuroblastic tumours.2025Clinical radiology
  23. A head-to-head prospective comparative analysis of 68Ga-DOTATATE PET/CT and 123I-MIBG SPECT/CT in central nervous system metastases of neuroblastoma and ganglioneuroblastoma.2025European journal of nuclear medicine and molecular imaging
  24. GD2-targeted theranostics of neuroblastoma with [64Cu]Cu/[177Lu]Lu-hu3F8.2025European journal of nuclear medicine and molecular imaging
  25. Radiomics-based prediction of pathological subtypes in peripheral neuroblastic tumors using 123I-MIBG SPECT/CT imaging: an observational study.2025European journal of pediatrics
  26. Development of [89Zr]Zr-DFO-hu3F8 and [225Ac]Ac-DOTA-hu3F8 Theranostic Pairs Targeting GD2 in Neuroblastomas.2025Journal of medicinal chemistry
  27. Differentiation of early relapse and late relapse in intermediate- and high-risk neuroblastoma with an 18F-FDG PET/CT-based radiomics nomogram.2024Abdominal radiology (New York)RCT
  28. Prognostic Value of Metabolic Parameters and Textural Features in Pretreatment 18F-FDG PET/CT of Primary Lesions for Pediatric Patients with Neuroblastoma.2024Academic radiology
  29. 18F-FDG PET/CT-Based Radiomics Nomogram for Prediction of Bone Marrow Involvement in Pediatric Neuroblastoma: A Two-Center Study.2024Academic radiology
  30. Whole-tumoral metabolic heterogeneity in 18F-FDG PET/CT is a novel prognostic marker for neuroblastoma.2024Cancer imaging : the official publication of the International Cancer Imaging Society
  31. Jaundice as a Rare Presentation of Neuroblastoma in a Pediatric Patient.2024Clinical nuclear medicine
  32. Coexistence of Langerhans Cell Histiocytosis and Ganglioneuroblastoma Revealed by 18 F-FDG PET/CT in a Pediatric Patient.2024Clinical nuclear medicine
  33. Solitary Dural Metastasis From Neuroblastoma Detected by 123 I-MIBG SPECT/CT.2024Clinical nuclear medicine
  34. Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging in pediatric opsoclonus myoclonus ataxia syndrome presenting with neuroblastoma.2024Pediatric radiology
  35. Predicting event-free survival after induction of remission in high-risk pediatric neuroblastoma: combining 123I-MIBG SPECT-CT radiomics and clinical factors.2024Pediatric radiology
  36. An Optimal Radiomics Nomogram Based on 18F-FDG PET/CT for Identifying Event-Free Survival in Pediatric Neuroblastoma.2023Academic radiology
  37. Axial Skeleton Radiomics of 18F-FDG PET/CT: Impact on Event-Free Survival Prediction in High-Risk Pediatric Neuroblastoma.2023Academic radiology
  38. Diagnostic Value of 18F-FDG PET/CT-Based Radiomics Nomogram in Bone Marrow Involvement of Pediatric Neuroblastoma.2023Academic radiology
  39. Leptomeningeal Metastasis From Neuroblastoma Revealed by 123 I-MIBG SPECT/CT.2023Clinical nuclear medicine
  40. Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification.2023Journal of cancer research and clinical oncology
  41. Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma.2023Seminars in nuclear medicine
  42. Clinical parameters combined with radiomics features of PET/CT can predict recurrence in patients with high-risk pediatric neuroblastoma.2022BMC medical imaging
  43. The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients.2022Cancer imaging : the official publication of the International Cancer Imaging Society
  44. MIBG Uptake in Pancreas as a Normal Variant.2022Clinical nuclear medicine
  45. The Diagnostic Value of 18F-FDG PET/CT Bone Marrow Uptake Pattern in Detecting Bone Marrow Involvement in Pediatric Neuroblastoma Patients.2022Contrast media & molecular imaging
  46. An 18F-FDG PET/CT radiomics nomogram for differentiation of high-risk and non-high-risk patients of the International Neuroblastoma Risk Group Staging System.2022European journal of radiology
  47. Diagnostic Value of Seven Different Imaging Modalities for Patients with Neuroblastic Tumors: A Network Meta-Analysis.2021Contrast media & molecular imaging

打开 PubMed 检索ClinicalTrials.gov

癌症

尤文肉瘤

Ewing sarcoma

2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.6%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 17 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。

这些数字背后的记录
论文中的科室影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

血液疾病

多发性骨髓瘤

Multiple myeloma

2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.06%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 15 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的多发性骨髓瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

血液疾病

噬血细胞性淋巴组织细胞增生症

Haemophagocytic lymphohistiocytosis

2021–2025 年中国大陆作者发表的 399 篇噬血细胞性淋巴组织细胞增生症 PubMed 英文论文中,这家医院牵头了 52 篇,占 13.0%。

牵头论文
52
2021–2025 年
牵头试验
24
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 161620212022: 9920222023: 7720232024: 111120242025: 992025

北京有 11 家医院列在噬血细胞性淋巴组织细胞增生症下全国有 66 家医院列在噬血细胞性淋巴组织细胞增生症下

这家医院参与的开放试验 4

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Prospective Single-Arm Clinical Trial of GO Regimen for HLH.
    分期
    II/III期
    开始
    2025-06
    登记号
    NCT07339345

    年龄 14 岁 至 70 岁(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  2. 即将招募
    Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections
    分期
    不分期
    开始
    2023-08
    登记号
    NCT05988177

    年龄 18 岁 至 未注明(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  3. 即将招募
    Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement
    分期
    未注明
    开始
    2023-12
    登记号
    NCT06131489

    年龄 18 岁 至 未注明(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  4. 正在招募
    A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])
    分期
    III期
    开始
    2025-11
    登记号
    NCT07208058

    年龄 16 岁 至 80 岁(登记的条件)

    牵头方不是列出的医院;另有 12 家列出的医院为研究中心上海、北京、南昌、广州、杭州、武汉、沈阳、石家庄、郑州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题诊断与预后治疗方案EB病毒与感染诱因
论文中的科室影像/核医学科神经内科眼科/神经眼科
牵头的论文52
  1. Monocyte/macrophages may exert prominent roles in macrophage activation syndrome.2025Annals of hematology免费全文
  2. Clinical and prognostic significance of whole blood Epstein-Barr virus DNA in patients with primary hemophagocytic lymphohistiocytosis: a retrospective observational study from China.2025Annals of hematology免费全文
  3. CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone).2025Annals of hematology免费全文
  4. Epstein-Barr virus infection and prognosis in haemophagocytic lymphohistiocytosis patients with underlying rheumatic diseases: a single-centre retrospective study.2025Clinical and experimental rheumatology
  5. The effectiveness of etoposide-containing chemotherapy regimens in the initial treatment of Hemophagocytic Syndrome in pregnancy.2025Hematology (Amsterdam, Netherlands)
  6. Epstein-Barr virus infection plays a crucial role in triggering hemophagocytic lymphohistiocytosis in patients with X-linked inhibitor of apoptosis protein deficiency.2025Hematology (Amsterdam, Netherlands)
  7. Off-label use of recombinant activated factor VII in hemophagocytic lymphohistiocytosis patients with major bleeding.2025Leukemia & lymphoma
  8. Exploring the Complexities of Liver Transplantation for Secondary Hemophagocytic Lymphohistiocytosis-Associated Acute Liver Failure.2025Pediatric transplantation
  9. Characteristics of epilepsy associated with hemophagocytic lymphohistiocytosis.2025Seizure
  10. The effectiveness of the doxorubicin-etoposide-methylprednisolone regimen for adult HLH secondary to rheumatic disease.2024Annals of hematology
  11. A convenient and practical index for predicting the induction response in adult patients with hemophagocytic lymphohistiocytosis: ferritin/platelet ratio.2024Annals of hematology免费全文
  12. Haemophagocytic lymphohistiocytosis caused by GATA2 deficiency: a report on three patients.2024BMC infectious diseases免费全文
  13. Transplantation in adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: yes or no?2024Blood
  14. Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells.2024Blood
  15. Enhancing diagnostic precision in EBV-related HLH: a multifaceted approach using 18F-FDG PET/CT and nomogram integration.2024Cancer imaging : the official publication of the International Cancer Imaging Society免费全文
  16. Etiological stratification and prognostic assessment of haemophagocytic lymphohistiocytosis by machine learning on onco-mNGS data and clinical data.2024Frontiers in immunology免费全文
  17. The efficacy and safety of chidamide in combination with etoposide and glucocorticoids for the treatment of hemophagocytic lymphohistiocytosis in adult patients: an open-label, single-center study.2024Frontiers in immunology免费全文
  18. Acute kidney injury in critical care: complications of hemophagocytic lymphohistiocytosis.2024Frontiers in immunology免费全文
  19. Beta 2-microglobulin is an independent risk marker of acute kidney injury in adult patients with hemophagocytic lymphohistiocytosis.2024Journal of nephrology免费全文
  20. Prognostic scoring system for pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis based on baseline characteristics: A multicenter retrospective study.2024Pediatric blood & cancerRCT
  21. Ocular Phenotypes in Patients With Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis in a Single Center Over 7 Years.2023American journal of ophthalmology
  22. Improved hemophagocytic lymphohistiocytosis index predicts prognosis of adult Epstein-Barr virus-associated HLH patients.2023Annals of medicine免费全文
  23. Biological therapies for hemophagocytic lymphohistiocytosis: current knowledge and future perspectives.2023Expert opinion on biological therapy
  24. Case Report: HAVCR2 mutation-associated Hemophagocytic lymphohistiocytosis.2023Frontiers in immunology免费全文
  25. Serum sCD25/ferritin ratio combined with MCP-1 is a valid predictor for identifying LAHS with HLH as the first manifestation.2023Journal of cancer research and clinical oncology免费全文
  26. Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study.2023Journal of cancer research and clinical oncology免费全文
  27. The diagnostic importance of multiple cytokines in adult hemophagocytic lymphohistiocytosis.2023Journal of clinical laboratory analysis免费全文
  28. L-DEP regimen is effective as an initial therapy for adult EBV-HLH.2022Annals of hematology
  29. Epstein-Barr virus central nervous system involvement in Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.2022Annals of hematology
  30. Clinical characteristics and treatment of NK/T-cell lymphoma-associated HLH.2022Annals of hematology
  31. Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy.2022Annals of medicine免费全文
  32. Macrophage activation syndrome in adults: Characteristics, outcomes, and therapeutic effectiveness of etoposide-based regimen.2022Frontiers in immunology免费全文
  33. The Outcome of Induction Therapy for EBV-Related Hemophagocytic Lymphohistiocytosis: A Model for Risk Stratification.2022Frontiers in immunology免费全文
  34. Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocytic lymphohistiocytosis in adults.2022Hematological oncology
  35. A Study on Early Death Prognosis Model in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis.2022Journal of healthcare engineering免费全文
  36. Development and Validation of 18F-FDG PET/CT-Based Multivariable Clinical Prediction Models for the Identification of Malignancy-Associated Hemophagocytic Lymphohistiocytosis.2022Korean journal of radiology免费全文
  37. Prognosis predicting value of semiquantitative parameters of visceral adipose tissue and subcutaneous adipose tissue of 18F-FDG PET/CT in newly diagnosed secondary hemophagocytic lymphohistiocytosis.2021Annals of nuclear medicine
  38. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial.2021British journal of haematology
  39. Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis.2021Cancer biology & therapy免费全文
  40. Autologous Hematopoietic Stem Cell Transplantation for Patients with Lymphoma-Associated Hemophagocytic lymphohistiocytosis.2021Cell transplantation免费全文
  41. Successful resolution of hemophagocytic lymphohistiocytosis during the chemotherapy course of acute myelocytic leukemia with ruxolitinib.2021Chinese medical journal免费全文
  42. Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis.2021Chinese medical journal免费全文
  43. Multiple-Organ Involvement in Familial Hemophagocytic Lymphohistiocytosis Type 2 Shown on FDG PET/CT.2021Clinical nuclear medicine
  44. Clinical and laboratory signs of haemophagocytic lymphohistiocytosis associated with pandemic influenza A (H1N1) infection in patients needing extracorporeal membrane oxygenation: A retrospective observational study.2021European journal of anaesthesiology
  45. Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment.2021Infectious diseases now
  46. Epstein-Barr virus infection is an important cause of hemophagocytic lymphohistiocytosis during chemotherapy for lymphoma.2021Infectious diseases now
  47. Hemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in an immunocompetent patient.2021Infectious diseases now
  48. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection.2021International immunopharmacology
  49. Non-EBV infection-associated hemophagocytic lymphohistiocytosis: a distinct subgroup where pathogen-directed therapy is essential and favorable outcomes are expected.2021Leukemia & lymphoma
  50. The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis.2021Leukemia & lymphoma
  51. Epidemiological investigation of hemophagocytic lymphohistiocytosis in China.2021Orphanet journal of rare diseases免费全文
  52. Clinical and laboratory characteristics of hemophagocytic lymphohistiocytosis induced by Leishmania infantum infection.2021PLoS neglected tropical diseases免费全文
中文论文(未计入)8
  1. [Clinical Characteristics Analysis of EBV-associated Hemophagocytic Lymphohistiocytosis Patients with Acute Kidney Injury].2024Zhongguo shi yan xue ye xue za zhi
  2. [Clinical and genetic mutation characteristics of patients with primary hemophagocytic lymphohistiocytosis and their impact on prognosis].2024Zhonghua yi xue za zhi
  3. [Characteristic and prognosis of patients with non-EBV infection-associated hemophagocytic lymphohistiocytosis].2022Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi免费全文
  4. [Evaluation of CD107a and perforin expression detection in the diagnosis of primary hemophagocytic lymphohistiocytosis].2022Zhonghua yi xue za zhi
  5. [New era of accurate diagnosis of hemophagocytic lymphohistiocytosis].2022Zhonghua yi xue za zhi
  6. [Interpretation of Chinese expert consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with lymphoma (2022)].2022Zhonghua yi xue za zhi
  7. [Exhaustion of CD8+T Lymphocytes Plays a Critical Role in the Pathogenesis of Secondary Hemophagocytic Lymphohistiocytosis].2021Zhongguo shi yan xue ye xue za zhi
  8. [Clinical study on the effect of etoposide-containing induction regimen for adult-onset Still's disease associated hemophagocytic syndrome].2021Zhonghua yi xue za zhi
它在 ClinicalTrials.gov 上的全部试验(任何状态)29
  1. Prospective Single-Arm Clinical Trial of GO Regimen for HLH.正在招募NCT07339345牵头方II/III期2025-06 启动
  2. Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections即将招募NCT05988177牵头方不分期2023-08 启动
  3. Segmental Resection Combined With DEP Regimen for EBV-HLH Patients With Intestinal Involvement即将招募NCT06131489牵头方2023-12 启动
  4. A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT状态不明NCT06491719牵头方不分期2024-07 启动
  5. Response Prediction in EBV-HLH Using Metabonomics Analysis状态不明NCT05677178牵头方2023-01 启动
  6. L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH已完成NCT05775705牵头方不分期2023-08 启动
  7. Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH状态不明NCT05546060牵头方I期2022-07 启动
  8. L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH状态不明NCT05315336牵头方III期2022-06 启动
  9. Prospective Study of Immune Function and PD-1 Antibody Therapy Efficacy Predictors on CAEBV and EBV-HLH Patients状态不明NCT05841342牵头方2022-10 启动
  10. Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH已完成NCT05600959牵头方2022-11 启动
  11. Zanubrutinib for HLH已完成NCT05320575牵头方III期2022-02 启动
  12. Clinical Study of Donor EBV-CTL Infusion in Patients With CAEBV and EBV-HLH After Allo-HSCT状态不明NCT05532826牵头方不分期2022-10 启动
  13. Rituximab Monotherapy for EBV-HLH and CAEBV状态不明NCT05384743牵头方III期2022-02 启动
  14. PD-1 Antibody Improve Mixed Chimerism状态不明NCT04944511牵头方不分期2021-07 启动
  15. Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH状态不明NCT05137522牵头方不分期2021-07 启动
  16. DEP Combine With PD-1 Antibody as an Treatment for EBV-HLH状态不明NCT05164978牵头方不分期2021-05 启动
  17. PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV状态不明NCT04084626牵头方III期2019-09 启动
  18. Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.状态不明NCT04077905牵头方III期2019-08 启动
  19. Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis状态不明NCT04120090牵头方III期2019-07 启动
  20. DEP-Ru Regimen as a Salvage Therapy for HLH状态不明NCT03533790牵头方III期2018-06 启动
  21. Etoposide in the First-line Treatment of Adult EBV-HLH状态不明NCT03742115牵头方III期2018-12 启动
  22. L-DEP as an Initial Treatment for EBV-HLH状态不明NCT02912702牵头方III期2016-09 启动
  23. Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology状态不明NCT02862054牵头方II/III期2015-01 启动
  24. L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis状态不明NCT02631109牵头方III期2015-12 启动
  25. A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])正在招募NCT07208058研究中心III期2025-11 启动
  26. A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects With Rheumatic and Immunological Disease-associated Haemophagocytic Lymphohistiocytosis (HLH) (Also Known as Macrophage Activation Syndrome (MAS))已完成NCT07034209研究中心II期2023-04 启动
  27. Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE已完成NCT05001737研究中心III期2021-12 启动
  28. Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome状态不明NCT04500886研究中心不分期2020-08 启动
  29. A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis(HLH)状态不明NCT04326348研究中心I期2020-07 启动
PubMed 以外找到的论文(未计入)8
  1. Anakinra for hemophagocytic lymphohistiocytosis: A real-world, multicenter retrospective study on efficacy, safety, and response durability2025Blood会议摘要
  2. Clinical and genetic features of primary hemophagocytic lymphohistiocytosis: A single-center analysis2025Blood会议摘要
  3. CXCL-9 and IL-18: Potential Biomarkers for Efficacy Evaluation in Refractory Hemophagocytic Lymphohistiocytosis Treated with RED (Ruxolitinib, Emapalumab and Dexamethasone)2024Blood会议摘要
  4. Rovadicitinib in Patients with Hemophagocytic Lymphohistiocytosis: A Single Arm, Open-Label, Phase I Study2024Blood会议摘要
  5. Zanubrutinib As Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis in Adults: A Single Center, Prospective Study2024Blood会议摘要
  6. Caebv Disease Originates from Infected Hematopoietic Stem Cells2023Blood会议摘要
  7. Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society2023Blood会议摘要
  8. P9.40: Liver Transplantation for Secondary Hemophagocytic Lymphohistiocytosis Associated Acute Liver Failure: A Case Report2022Transplantation会议摘要

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血友病 A

Haemophilia A

2021–2025 年没有牵头血友病 A的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

北京有 15 家医院列在血友病 A下全国有 160 家医院列在血友病 A下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    分期
    未注明
    开始
    2024-11
    登记号
    NCT06727669

    年龄未注明(登记的条件)

    牵头:北京大学人民医院;另有 4 家列出的医院为研究中心北京、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Longitudinal Cohort of Thrombosis and Hemostasis Diseases正在招募NCT06727669研究中心2024-11 启动

打开 PubMed 检索ClinicalTrials.gov

血液疾病

血栓性血小板减少性紫癜

Thrombotic thrombocytopenic purpura

2021–2025 年没有牵头血栓性血小板减少性紫癜的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头

北京有 8 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Longitudinal Cohort of Thrombosis and Hemostasis Diseases
    分期
    未注明
    开始
    2024-11
    登记号
    NCT06727669

    年龄未注明(登记的条件)

    牵头:北京大学人民医院;另有 4 家列出的医院为研究中心北京、郑州、重庆

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Longitudinal Cohort of Thrombosis and Hemostasis Diseases正在招募NCT06727669研究中心2024-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgG4相关性疾病

IgG4-related disease

2021–2025 年中国大陆作者发表的 246 篇IgG4相关性疾病 PubMed 英文论文中,这家医院牵头了 12 篇,占 4.9%。

牵头论文
12
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 3320222023: 1120232024: 3320242025: 552025

北京有 11 家医院列在IgG4相关性疾病下全国有 46 家医院列在IgG4相关性疾病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
    分期
    I/II期
    开始
    2026-01
    登记号
    NCT07061938

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 5 家列出的医院为研究中心上海、北京、成都、武汉

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题治疗与复发诊断与鉴别头颈、眼眶与唾液腺
论文中的科室风湿免疫科消化/肝病科眼科/神经眼科
牵头的论文12
  1. Does adjunctive endoscopic biliary drainage improve outcomes beyond glucocorticoids alone in IgG4-related pancreatobiliary disease?2025BMC gastroenterology免费全文
  2. Correlations between IgG4-related disease and allergic reactions: implications for future therapeutic strategies.2025Clinical and experimental rheumatology
  3. Animal models of IgG4-related disease.2025Clinical immunology (Orlando, Fla.)
  4. Risk factors for relapse of IgG4-related disease: a systematic review and meta‑analysis.2025Clinical rheumatology
  5. Diagnostic value of a novel salivary gland ultrasound scoring system in IgG4-related sialadenitis.2025Rheumatology (Oxford, England)
  6. Systematic analysis for clinical characteristics and outcomes of IgG4-related disease patients during the COVID-19 pandemic.2024Clinical rheumatology
  7. Performance of the 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease in a Large Chinese Cohort.2024Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases
  8. Three cases of IgG4-RD complicated by splenic artery aneurysm: a complication of IgG4-RD?2024RMD open免费全文
  9. Association Between Immunoglobulin G4-Related Ophthalmic Disease and Nonlymphoid Malignancy Case Series and Comprehensive Review of the Literature.2023Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society免费全文
  10. Clinical characteristics of IgG4-related respiratory disease patients: a large Chinese cohort study.2022Clinical and experimental rheumatology
  11. Clinical characteristics and therapeutic response of immunoglobulin G4-related disease: a retrospective study of 127 Chinese patients.2022Orphanet journal of rare diseases免费全文
  12. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.2022Rheumatology (Oxford, England)
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease正在招募NCT07061938研究中心I/II期2026-01 启动
  2. Withdraw Drug in Stable IgG4-Related Disease状态不明NCT04124861研究中心不分期2020-06 启动
PubMed 以外找到的论文(未计入)1
  1. Biliary candidiasis mimicking IgG4‐related disease in a patient with normal immunity2022Rheumatology & autoimmunity论文

打开 PubMed 检索ClinicalTrials.gov

其他疾病

重症肌无力

Myasthenia gravis

2021–2025 年中国大陆作者发表的 499 篇重症肌无力 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.2%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 11 家医院列在重症肌无力下全国有 93 家医院列在重症肌无力下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的重症肌无力开放试验。

这些数字背后的记录
研究主题眼肌型重症肌无力
论文中的科室神经内科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

肝豆状核变性

Wilson disease

2021–2025 年中国大陆作者发表的 201 篇肝豆状核变性 PubMed 英文论文中,这家医院牵头了 4 篇,占 2.0%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 2220222023: 0020232024: 0020242025: 222025

北京有 3 家医院列在肝豆状核变性下全国有 28 家医院列在肝豆状核变性下

这家医院参与的开放试验 2

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    China Registry for Genetic / Metabolic Liver Diseases
    分期
    未注明
    开始
    2015-06
    登记号
    NCT03131427

    年龄未注明(登记的条件)

    牵头:首都医科大学附属北京友谊医院;另有 1 家列出的医院为研究中心北京

  2. 正在招募
    Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.
    分期
    III期
    开始
    2026-09
    登记号
    NCT07465718

    年龄 8 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 3 家列出的医院为研究中心北京、杭州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
研究主题遗传学(ATP7B)诊断与铜代谢检测肝病与肝移植
论文中的科室消化/肝病科
牵头的论文4
  1. Dysfunction of ATP7B Splicing Variant Caused by Enhanced Interaction With COMMD1 in Wilson Disease.2025Cellular and molecular gastroenterology and hepatology免费全文
  2. Hepatic progenitor cells reprogrammed from mouse fibroblasts repopulate hepatocytes in Wilson's disease mice.2025Stem cell research & therapy免费全文
  3. Laboratory and clinical evaluation of a microarray for the detection of ATP7B mutations in Wilson disease in China.2022Journal of clinical laboratory analysis免费全文
  4. Identification of potential modifier genes in Chinese patients with Wilson disease.2022Metallomics : integrated biometal science免费全文
中文论文(未计入)3
  1. [Progress in drug therapy of Wilson's disease].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  2. [Reappraisal on the clinical diagnosis and treatment of hereditary liver diseases].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology免费全文
  3. [Construction and analysis of transcriptome-based hepatolenticular degeneration regulatory network].2022Sheng wu gong cheng xue bao = Chinese journal of biotechnology
它在 ClinicalTrials.gov 上的全部试验(任何状态)2
  1. China Registry for Genetic / Metabolic Liver Diseases正在招募NCT03131427牵头方2015-06 启动
  2. Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.正在招募NCT07465718研究中心III期2026-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

胆道闭锁

Biliary atresia

2021–2025 年中国大陆作者发表的 214 篇胆道闭锁 PubMed 英文论文中,这家医院牵头了 4 篇,占 1.9%。

牵头论文
4
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 2220212022: 0020222023: 1120232024: 0020242025: 112025

北京有 3 家医院列在胆道闭锁下全国有 28 家医院列在胆道闭锁下

截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的胆道闭锁开放试验。

这些数字背后的记录
研究主题肝移植术后并发症发病机制
论文中的科室消化/肝病科普外/肝胆胰外科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年中国大陆作者发表的 187 篇大动脉炎 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.1%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

北京有 30 家医院列在大动脉炎下全国有 108 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
论文中的科室影像/核医学科风湿免疫科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

特发性肺纤维化

Idiopathic pulmonary fibrosis

2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.1%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

北京有 27 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
    分期
    III期
    开始
    2026-09
    登记号
    NCT07687459

    年龄 40 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 45 家列出的医院为研究中心Yuncheng、上海、乌鲁木齐、北京、南京、南宁、南昌、南阳、厦门、合肥、呼和浩特、天津、太原、宁波、宜昌、广州、徐州、成都、昆明、杭州、武汉、沈阳、济南、海口、温州、石家庄、福州、西安、郑州、长春、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

庞贝病

Pompe disease

2021–2025 年中国大陆作者发表的 30 篇庞贝病 PubMed 英文论文中,这家医院牵头了 1 篇,占 3.3%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

北京有 6 家医院列在庞贝病下全国有 30 家医院列在庞贝病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的庞贝病开放试验。

这些数字背后的记录
论文中的科室儿科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

北京有 24 家医院列在白塞病下全国有 149 家医院列在白塞病下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease
    分期
    III期
    开始
    2023-11
    登记号
    NCT06145893

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 20 家列出的医院为研究中心上海、临沂、北京、南昌、厦门、太原、广州、徐州、杭州、桂林、深圳、温州、石家庄、苏州

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文1
  1. Integrated Analysis of Intersecting Neutrophil Signatures in Behçet's Disease and Inflammatory Bowel Disease.2025International journal of rheumatic diseases
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease正在招募NCT06145893研究中心III期2023-11 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

IgA 肾病

IgA nephropathy

2021–2025 年没有牵头IgA 肾病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 32 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。

这些数字背后的记录
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression进行中,不再招募NCT05797610研究中心III期2023-08 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

戈谢病

Gaucher disease

2021–2025 年中国大陆作者发表的 30 篇戈谢病 PubMed 英文论文中,这家医院牵头了 2 篇,占 6.7%。

牵头论文
2
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

北京有 5 家医院列在戈谢病下全国有 41 家医院列在戈谢病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的戈谢病开放试验。

这些数字背后的记录
论文中的科室儿科
牵头的论文2
  1. Global Epidemiology of Gaucher Disease: an Updated Systematic Review and Meta-analysis.2023Journal of pediatric hematology/oncology
  2. Update of treatment for Gaucher disease.2022European journal of pharmacology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性胆汁性胆管炎

Primary biliary cholangitis

2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 12 篇,占 4.0%。

牵头论文
12
2021–2025 年
牵头试验
2
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
2
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 4420222023: 1120232024: 2220242025: 332025

北京有 16 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    PBC Long-term Outcomes Study
    分期
    未注明
    开始
    2025-05
    登记号
    NCT07149675

    年龄未注明(登记的条件)

    牵头:首都医科大学附属北京友谊医院北京

  2. 正在招募
    A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
    分期
    III期
    开始
    2025-12
    登记号
    NCT07282353

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 35 家列出的医院为研究中心Baoji、上海、临沂、北京、十堰、南京、南宁、南昌、厦门、台州、合肥、哈尔滨、天津、成都、杭州、沈阳、深圳、湛江、福州、西安、郑州、重庆、长春、长沙、青岛

  3. 正在招募
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    分期
    III期
    开始
    2023-09
    登记号
    NCT06051617

    年龄 18 岁 至 未注明(登记的条件)

    牵头方不是列出的医院;另有 17 家列出的医院为研究中心上海、乌鲁木齐、北京、合肥、广州、成都、杭州、武汉、福州、西安、贵阳、郑州、重庆、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科
牵头的论文12
  1. Autoimmune liver diseases in the Asia Pacific region: proceedings of the autoimmune liver disease course at APASL 2025.2026Hepatology international
  2. Double-negative T cells in combination with ursodeoxycholic acid ameliorates immune-mediated cholangitis in mice.2025BMC medicine
  3. GLOBE Score and UK-PBC Risk Score Predict Long-Term Clinical Outcomes of Patients With Primary Biliary Cholangitis and Receiving Ursodeoxycholic Acid and Fenofibrate.2025Journal of digestive diseases
  4. Clinicopathologic Features of a Rare and Underrecognized Variant of Early-stage Primary Biliary Cholangitis With Ductopenia.2025The American journal of surgical pathology
  5. Primary Biliary Cholangitis Associated with Ulcerative Colitis: Case Series and Literature Review.2024Medicina (Kaunas, Lithuania)
  6. Obliteration of portal venules contributes to portal hypertension in biliary cirrhosis.2024The Journal of pathology
  7. Concomitant gallstone disease was not associated with long-term outcomes in ursodeoxycholic acid-treated patients with primary biliary cholangitis.2023Journal of digestive diseases
  8. Concomitant extrahepatic autoimmune diseases do not compromise the long-term outcomes of primary biliary cholangitis.2022Hepatobiliary & pancreatic diseases international : HBPD INT
  9. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis.2022Hepatology international
  10. Reciprocal alterations in circulating and hepatic gamma-delta T cells in patients with primary biliary cholangitis.2022Hepatology international
  11. Rare liver diseases are not rare in China.2022Liver international : official journal of the International Association for the Study of the Liver
  12. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta-analysis.2021Journal of gastroenterology and hepatology
中文论文(未计入)3
  1. [Research progress on early-stage primary biliary cholangitis accompanied by portal hypertension].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  2. [Clinical features and long-term prognosis of primary biliary cholangitis in patients with past hepatitis B virus infection].2023Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  3. [Recommendations of APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis].2022Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
早期论文(2016–2020 年)10
  1. Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.2019Hepatology international
  2. Prognosis of 732 ursodeoxycholic acid-treated patients with primary biliary cholangitis: A single center follow-up study from China.2019Journal of gastroenterology and hepatology
  3. Alteration of liver-infiltrated and peripheral blood double-negative T-cells in primary biliary cholangitis.2019Liver international : official journal of the International Association for the Study of the Liver
  4. Efficacy and safety of fenofibrate add-on therapy for patients with primary biliary cholangitis and a suboptimal response to UDCA.2018Revista espanola de enfermedades digestivas
  5. A brief review on prognostic models of primary biliary cholangitis.2017Hepatology international
  6. [Risk factors and therapeutic strategies for primary biliary cholangitis patients with poor prognosis].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  7. [Research advances in primary biliary cholangitis].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  8. Optimal Adaptive Statistical Iterative Reconstruction Percentage in Dual-energy Monochromatic CT Portal Venography.2016Academic radiology
  9. Quantitative fibrosis parameters highly predict esophageal-gastro varices in primary biliary cirrhosis.2016European review for medical and pharmacological sciences
  10. Dual Energy CT (DECT) Monochromatic Imaging: Added Value of Adaptive Statistical Iterative Reconstructions (ASIR) in Portal Venography.2016PloS one
它在 ClinicalTrials.gov 上的全部试验(任何状态)8
  1. PBC Long-term Outcomes Study正在招募NCT07149675牵头方2025-05 启动
  2. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis已完成NCT01857284牵头方III期2009-09 启动
  3. A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA正在招募NCT07282353研究中心III期2025-12 启动
  4. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis正在招募NCT06051617研究中心III期2023-09 启动
  5. CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)进行中,不再招募NCT05896124研究中心II期2023-08 启动
  6. Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary Cholangitis已完成NCT05190523研究中心II期2022-04 启动
  7. Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis已完成NCT05450887研究中心III期2021-09 启动
  8. A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis进行中,不再招募NCT05050136研究中心II期2021-09 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

原发性硬化性胆管炎

Primary sclerosing cholangitis

2021–2025 年中国大陆作者发表的 100 篇原发性硬化性胆管炎 PubMed 英文论文中,这家医院牵头了 4 篇,占 4.0%。

牵头论文
4
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
1
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 1120242025: 112025

北京有 10 家医院列在原发性硬化性胆管炎下全国有 90 家医院列在原发性硬化性胆管炎下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
    分期
    III期
    开始
    2026-05
    登记号
    NCT07387549

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 11 家列出的医院为研究中心上海、北京、南昌、天津、广州、济南、郑州、长春

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。

这些数字背后的记录
论文中的科室消化/肝病科影像/核医学科

打开 PubMed 检索ClinicalTrials.gov

其他疾病

先天性巨结肠

Hirschsprung disease

2021–2025 年没有牵头先天性巨结肠的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

北京有 8 家医院列在先天性巨结肠下全国有 82 家医院列在先天性巨结肠下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的先天性巨结肠开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他相关研究

联系这家医院

出示给工作人员或司机的院名卡

首都医科大学附属北京友谊医院

Beijing Friendship Hospital

北京

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请以上方链接的医院官方页面为准。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Capital Medical University Affiliated Beijing Friendship Hospital; Beijing Friendship Hospital Affiliated to Capital Medical University; Beijing Friendship Hospital of Capital Medical University; Beijing friendship hospital; Beijing Friendship Hospital Cancer Center; Beijing Friendship Hospita; Library of Beijing Friendship Hospital; Beijing Friendship Hospital of the Capital Medical University

提出更正下载数据